Arsenal-backed Caprion Biosciences to merge with HistoGeneX

Caprion Biosciences, a portfolio company of Arsenal Capital Partners, is combining with HistoGeneX. Financial terms weren’t announced. HistoGeneX is backed by Waterland Private Equity Investments. HistoGeneX provides pathology and biomarker assessment services for drug development.

DealsNorth AmericaUSHealthcareBriefs